Oncogene-Induced Senescence Suppression in Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing differentiated blood cells, such as megakaryocytic cells and platelets, face challenges in achieving a stable and sufficient supply due to limitations in amplifying progenitor cells and inducing differentiation efficiently, particularly in large quantities and maintaining cell growth without oncogene-induced senescence.
Innovation Solution
The method involves forcibly expressing an oncogene, like c-MYC, in cells during differentiation to enhance growth and suppress oncogene-induced senescence by using polycomb genes like BMI1, allowing for the production of megakaryocytic progenitor cells with high growth ability and enabling the stable production of megakaryocytic cells and platelets from induced pluripotent stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional differentiation induction methods are used, then differentiated blood cells can be produced, but the quantity is insufficient and production is unstable
Solution Approach 1:
The patent applies preliminary action by introducing and activating oncogenes (c-MYC, L-MYC, N-MYC) before the differentiation process to pre-establish high growth capability in the progenitor cells. This preliminary genetic modification ensures that cells are primed for rapid proliferation prior to differentiation induction, thereby guaranteeing sufficient cell quantity and production stability throughout the differentiation process
Solution Approach 2:
The patent employs parameter changes by modifying the genetic state of cells through oncogene introduction and activation. This changes the fundamental growth parameters of the progenitor cells, transforming them from normal growth rates to accelerated proliferation rates, which directly addresses the insufficient quantity issue while maintaining production stability
2Productivity
If oncogenes are forcibly expressed to amplify cell growth, then cell quantity increases, but oncogene-induced senescence occurs
Solution Approach 1:
The patent uses polycomb group genes (BMI1, BCL6) as intermediaries that mediate between oncogene expression and senescence prevention. These polycomb genes act as protective factors that counterbalance the senescence-inducing effects of oncogenes, allowing sustained high-level oncogene expression without triggering cell senescence, thus maintaining both productivity and cell viability
Solution Approach 2:
The patent extracts or removes the harmful senescence effect by introducing polycomb group genes that specifically counteract senescence pathways. This separation allows the beneficial growth-promoting effects of oncogenes to be maintained while the harmful senescence induction is actively suppressed through the introduced protective genetic elements
Data Source
AI summary
The present invention has an object of providing a method for producing specific cells by amplifying cells in a desired differentiation stage. The present invention provides a method for producing specific cells by inducing differentiation of cells, wherein an oncogene is forcibly expressed in cells in a desired differentiation stage to amplify the cells in the desired differentiation stage. The present invention also provides a method for producing specific cells, wherein oncogene-induced senescence (OIS) which is induced by the oncogene expressed in the cells in the desired differentiation stage is suppressed.